+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
INFINIUM

Infinium Pharmachem Share Price

 

 

Infinium Pharmachem live price: ₹214. It opened at ₹215 vs previous close ₹210; intraday high/low: ₹215/₹212. The 50 & 200 DMA stand at ₹209.06/₹226.18.

Infinium Pharmachem Performance

  • Today's Low
  • ₹212
  • Today's High
  • ₹215
  • 52 Week Low
  • ₹189
  • 52 Week High
  • ₹304
  • Open Price₹215
  • Previous Close₹210
  • Volume2,500
  • 50 DMA₹209.06
  • 100 DMA₹214.14
  • 200 DMA₹226.18

Infinium Pharmachem Chart

Investment Returns

  • Over 1 Month + 1.47%
  • Over 3 Month + 5.71%
  • Over 6 Month -3.21%
  • Over 1 Year -26.71%

Smart Investing Starts Here Start SIP with Infinium Pharmachem for Steady Growth!

Invest Now

Infinium Pharmachem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21
  • PEG Ratio
  • -
  • Market Cap Cr
  • 298
  • P/B Ratio
  • 2.5
  • Average True Range
  • 7.61
  • EPS
  • 7.8
  • Dividend Yield
  • 0
  • MACD Signal
  • -2
  • RSI
  • 56.26
  • MFI
  • 65.83

Infinium Pharmachem Financials

Infinium Pharmachem Technicals

EMA & SMA

Current Price
₹214.00
+ 4.2 (2%)
pointer
  • Bearish Moving Average 4
  • Bullish Moving Average 12
  • 20 Day
  • ₹206.90
  • 50 Day
  • ₹209.10
  • 100 Day
  • ₹214.10
  • 200 Day
  • ₹226.20

Resistance and Support

213.62 Pivot Speed
  • R3 217.03
  • R2 215.77
  • R1 214.88
  • S1 212.73
  • S2 211.47
  • S3 210.58

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Infinium Pharmachem Ltd has an operating revenue of Rs. 345.34 Cr. on a trailing 12-month basis. An annual revenue growth of 22% is outstanding, Pre-tax margin of 9% is okay, ROE of 11% is good. The company has a reasonable debt to equity of 6%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 86 which is a GOOD score indicating consistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 89 indicates it belongs to a poor industry group of Comml Svcs-Healthcare and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Infinium Pharmachem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-29 Audited Results & Others To consider other business matters. issue in the ratio of 1:1 of Rs. 10/-.
2026-03-13 Others To consider other business matters. issue in the ratio of 1:1 of Rs. 10/-.
2025-11-13 Quarterly Results
2025-08-21 Others To consider other business matters. issue in the ratio of 1:1 of Rs. 10/-.
2025-05-28 Audited Results & Others To consider other business matters. (Revised) issue in the ratio of 1:1 of Rs. 10/-.
Date Purpose Remarks
2023-09-13 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Infinium Pharmachem Shareholding Pattern

64.91%
31.96%
3.13%

Infinium Pharmachem FAQs

Infinium Pharmachem share price is ₹214 As on 22 June, 2026 | 20:16

The Market Cap of Infinium Pharmachem is ₹297.8 Cr As on 22 June, 2026 | 20:16

The P/E ratio of Infinium Pharmachem is 21 As on 22 June, 2026 | 20:16

The PB ratio of Infinium Pharmachem is 2.5 As on 22 June, 2026 | 20:16

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23